Leica Biosystems to Acquire Statlab Medical Products

Dow Jones

07/15

Leica Biosystems, an operating company of $Danaher Corp(DHR-W)$., said it would acquire StatLab Medical Products, a developer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity.

Leica President Gustavo Perez Fernandez said the partnership would allow its laboratories to achieve consistency, standardization and quality required to adopt artificial intelligence-enabled cancer diagnostics at scale.

Leica focuses on cancer diagnostics and digital pathology solutions under Danaher, a global science and technology company that owns brands including Cytiva, Cepheid and Beckman Coulter.

The transaction is expected to close by the end of 2026. Financial terms were not disclosed.

Write to Grace Yoon at grace.yoon@wsj.com

(END) Dow Jones Newswires

July 14, 2026 17:11 ET (21:11 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2651481063"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651481063\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651481063?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 05:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651481063","market":"sg","top_or_hot":-1,"title":"Leica Biosystems to Acquire Statlab Medical Products","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Leica Biosystems, an operating company of $Danaher Corp(DHR-W)$., said it would acquire StatLab Medical Products, a developer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity. \n</p>\n<p>\n  Leica President Gustavo Perez Fernandez said the partnership would allow its laboratories to achieve consistency, standardization and quality required to adopt artificial intelligence-enabled cancer diagnostics at scale. \n</p>\n<p>\n  Leica focuses on cancer diagnostics and digital pathology solutions under Danaher, a global science and technology company that owns brands including Cytiva, Cepheid and Beckman Coulter. \n</p>\n<p>\n  The transaction is expected to close by the end of 2026. Financial terms were not disclosed. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 17:11 ET (21:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Leica Biosystems to Acquire Statlab Medical Products</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLeica Biosystems to Acquire Statlab Medical Products\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-07-15 05:11</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Leica Biosystems, an operating company of $Danaher Corp(DHR-W)$., said it would acquire StatLab Medical Products, a developer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity. \n</p>\n<p>\n  Leica President Gustavo Perez Fernandez said the partnership would allow its laboratories to achieve consistency, standardization and quality required to adopt artificial intelligence-enabled cancer diagnostics at scale. \n</p>\n<p>\n  Leica focuses on cancer diagnostics and digital pathology solutions under Danaher, a global science and technology company that owns brands including Cytiva, Cepheid and Beckman Coulter. \n</p>\n<p>\n  The transaction is expected to close by the end of 2026. Financial terms were not disclosed. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Grace Yoon at grace.yoon@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 14, 2026 17:11 ET (21:11 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999001176.SGD","symbol_name":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2651481063","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651481063","pubTimestamp":1784063460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Leica Biosystems, an operating company of Danaher Corp., said it would acquire StatLab Medical Products, a developer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity.Leica President Gustavo Perez Fernandez said the partnership would allow its laboratories to achieve consistency, standardization and quality required to adopt artificial intelligence-enabled cancer diagnostics at scale.Leica focuses on cancer diagnostics and digital pathology solutions under Danaher, a global science and technology company that owns brands including Cytiva, Cepheid and Beckman Coulter.The transaction is expected to close by the end of 2026. Financial terms were not disclosed.Write to Grace Yoon at grace.yoon@wsj.com Dow Jones NewswiresJuly 14, 2026 17:11 ET Copyright  2026 Dow Jones & Company, Inc.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","IE00BQXX3F31.USD":"GUINNESS GLOBAL INNOVATORS \"C\" (USD) ACC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","BK4121":"生命科学工具和服务","LU2211814178.USD":"ALLIANZ CLEAN PLANET \"AT\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","LU1366333091.USD":"FIDELITY GLOBAL FOCUS \"A\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4585":"ETF&股票定投概念","LU2355687059.USD":"NORDEA 1 GLOBAL IMPACT  \"BP\" (USD) ACC","LU1923621640.USD":"Natixis Thematics Water R/A USD","BK4534":"瑞士信贷持仓","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","DHR":"丹纳赫","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","FMED":"Fidelity Disruptive Medicine ETF","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0157215616.USD":"FIDELITY GLOBAL FOCUS \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1923622614.USD":"Natixis Thematics Meta R/A USD","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU0312595415.SGD":"Schroder ISF Global Climate Change Equity A Acc SGD","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","IE00BQXX3D17.EUR":"GUINNESS GLOBAL INNOVATORS \"C\" (EUR) ACC","LU0107464264.USD":"abrdn SICAV I - GLOBAL INNOVATION EQUITY \"A\" (USD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC"},"translate_title":"徕卡生物系统将收购 Statlab Medical Products","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DHR":0.9,"FMED":0.6},"content_text":"Leica Biosystems, an operating company of $Danaher Corp(DHR-W)$., said it would acquire StatLab Medical Products, a developer of anatomical pathology products, from Linden Capital Partners and Audax Private Equity. \n\n\n  Leica President Gustavo Perez Fernandez said the partnership would allow its laboratories to achieve consistency, standardization and quality required to adopt artificial intelligence-enabled cancer diagnostics at scale. \n\n\n  Leica focuses on cancer diagnostics and digital pathology solutions under Danaher, a global science and technology company that owns brands including Cytiva, Cepheid and Beckman Coulter. \n\n\n  The transaction is expected to close by the end of 2026. Financial terms were not disclosed. \n\n\n \n\n\n  Write to Grace Yoon at grace.yoon@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 14, 2026 17:11 ET (21:11 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}